SecBot SecBot
8-K ·Filed Jun 10, 2026

MASI

MASIMO CORP
BULLISH
Impact 8/10
Horizonimmediate Processed5mo ago SEC0001104659-26-072151
8-K material event: Items 1.02, 2.01, 5.01
Actionable Insight ▲ Bullish

The acquisition has closed, MASI shareholders have been cashed out at $180/share. Any remaining shares should be tendered for the merger consideration. Monitor Danaher (DHR) for integration updates and potential synergies in the medical technology segment.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK AT ENTRY AT T+5
Entry
$179.95
T+0 close · Jun 10, 2026 · via day close
Latest settled
0.00%
T+5 · $179.95
Vs SPY
−2.14%
α at T+5
Next horizon
T+20
due 4mo ago
  1. T+0 · Jun 10 $179.95entry
  2. T+1 · 5mo ago 0.00%α −1.70% · $179.95
  3. T+5 · 5mo ago 0.00%α −2.14% · $179.95
  4. T+20 · due 4mo ago Pending
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Danaher Corporation has completed its acquisition of Masimo Corp on June 10, 2026, with Masimo shareholders receiving $180.00 per share in cash, representing a 38% premium to the pre-announcement price. Masimo's common stock ceased trading on Nasdaq and will be deregistered, with the company becoming a wholly owned subsidiary of Danaher. The Merger Agreement's credit facility was terminated and repaid, the board was replaced, and three executives (Catherine Szyman, Gregory Meehan, Charles Dadswell) entered into separation and consulting agreements for a three-month transition period.

Key Facts

  • Danaher completed the acquisition of Masimo Corp on June 10, 2026, with Masimo becoming a wholly owned subsidiary of Danaher.
  • Masimo shareholders received $180.00 per share in cash, a 38% premium to the pre-announcement stock price.
  • Masimo's common stock ceased trading on Nasdaq prior to the market open on the Closing Date and will be deregistered via Form 25 and Form 15.
  • Six directors resigned from the Masimo board at the Effective Time; Frank McFaden (director of Merger Sub) became the sole director of the surviving corporation.
  • The company terminated and repaid all obligations under its Credit Agreement with Bank of America dated December 1, 2025.
  • Catherine Szyman, Gregory Meehan, and Charles Dadswell entered into separation and consulting agreements with a 3-month consulting period post-closing.
  • Parent funded the acquisition with cash on hand.

Financial Impact

Danaher acquired Masimo for approximately $9.4 billion, paying $180.00 per share in cash. The premium to pre-announcement price was approx. 38%.

revenueearningscash-flow

Risk Factors

  • Integration risk: combining Masimo's operations with Danaher's existing life sciences portfolio could face execution challenges.
  • Regulatory risk: potential antitrust or regulatory conditions attached to the merger could impose operational constraints.
  • Key personnel risk: three senior executives (Catherine Szyman, Gregory Meehan, Charles Dadswell) have departed, with only a 3-month consulting transition period.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
40% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-072151
Document: tm2617395d1_ex3-2.htm0001104659-26-072151
Document: tm2617395d1_8k.htm0001104659-26-072151
Document: tm2617395d1_ex3-1.htm0001104659-26-072151
Document: 0001104659-26-072151-index-headers.html0001104659-26-072151
Document: 0001104659-26-072151-index.html0001104659-26-072151
Document: 0001104659-26-072151.txt0001104659-26-072151

Track record

10 reports on MASI

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +1.94% at T+60 after the Feb 27, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Oct 12, 20265w ago Institutional Cluster Bearish 4/10 No price data
  2. Jun 22, 202621w ago 15-12G Neutral 4/10 No price data
  3. Jun 10, 202622w ago 8-K Bullish 8/10 Viewing Entry $179.95 No price data
  4. May 4, 202628w ago 8-K Bullish 8/10 Entry $177.90 to $178.59 ▲ +0.39% −5.26% vs SPY
  5. Apr 21, 202629w ago Court Ruling Bearish 6/10 Entry $178.21 to $178.80 ▼ −0.33% +4.59% vs SPY
  6. Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $177.95 to $178.46 ▲ +0.28% −9.44% vs SPY
  7. Mar 18, 202634w ago PREM14A Neutral 4/10 Entry $178.51 to $177.96 ▼ −0.31% −7.93% vs SPY
  8. Feb 27, 202637w ago DFAN14A Bullish 9/10 Entry $175.27 to $177.00 ▲ +0.99% +8.93% vs SPY
  9. Jan 23, 202642w ago Court Ruling Neutral 2/10 Entry $142.48 No price data
  10. Jan 23, 202642w ago Court Ruling Neutral 2/10 Entry $142.48 No price data
Showing 10 of 10

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026